Good morning :)
Place Order
Add to Watchlist

Bajaj Healthcare Ltd

BAJAJHCARE

Bajaj Healthcare Ltd

BAJAJHCARE
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,426 cr, stock is ranked 1,329
High RiskStock is 3.02x as volatile as Nifty
451.700.53% (+2.40)
451.700.53% (+2.40)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,426 cr, stock is ranked 1,329
High RiskStock is 3.02x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,426 cr, stock is ranked 1,329
High RiskStock is 3.02x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-91.925.130.19%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.536.560.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Bajaj Healthcare Ltd manufactures active pharmaceutical ingredients and formulations, focusing on amino acids and nutritional supplements for healthcare industries.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 5.37%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.17% to 0.13%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue223.22233.04329.18371.14416.54663.89681.33647.39482.11521.72
Raw Materialssubtract128.77131.50215.43245.33268.32377.19409.91393.84264.43476.16
Power & Fuel Costsubtract14.1216.7919.8121.8324.2424.9631.8337.6931.47
Employee Costsubtract16.9319.5721.6524.6228.1834.5541.1142.3243.85
Selling & Administrative Expensessubtract6.015.685.687.318.0012.9114.8614.8616.21
Operating & Other expensessubtract26.9626.2825.1028.1632.9871.0063.5266.11154.92
Depreciation/Amortizationsubtract9.2911.3511.0811.4112.1216.1217.6417.2127.6228.19
Interest & Other Itemssubtract7.648.207.738.326.638.3412.7817.6829.7528.98
Taxes & Other Itemssubtract5.295.877.507.8610.8235.7118.3014.65-2.353.91
EPS2.281.432.752.954.5715.0617.2415.59-30.36-5.62
DPS0.000.000.250.000.001.381.501.001.001.00
Payout ratio0.000.000.090.000.000.090.090.06-0.18

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

Aug 18PDF
FY 2022

Annual report

PDF

Investor Presentation

Jun 27PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Bajaj Healthcare Ltd-17.035.130.19%
Sun Pharmaceutical Industries Ltd45.356.470.75%
Cipla Ltd28.514.380.89%
Torrent Pharmaceuticals Ltd68.4516.540.84%

Price Comparison

Compare BAJAJHCARE with any stock or ETF
Compare BAJAJHCARE with any stock or ETF
BAJAJHCARE
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 8.55%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Increased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 1.06%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding59.19%1.31%0.66%1.07%37.78%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.69%0.66%0.74%0.53%0.01%1.07%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.31%

Top 1 Mutual Funds holding Bajaj Healthcare Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HDFC Pharma and Healthcare Fund - Growth - Direct Plan

Growth
1.3794%1.14%1.14%37/37 (-1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 23, 2024

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 23, 2024

Cash Dividend

Ex DateEx DateSep 22, 2023

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 22, 2023

Cash Dividend

Ex DateEx DateSep 22, 2022

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Sep 22, 2022

Cash Dividend

Ex DateEx DateSep 28, 2021

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 28, 2021

Cash Dividend

Ex DateEx DateSep 28, 2021

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 28, 2021

News & Opinions
Spotlight
Bajaj Healthcare hits 52-week high on TGA nod for Vadodara unit

The approval is valid for a period of 24 months. The said site has already received approval from United States Food and Drug Administration (USFDA) and European Union. The pharmaco stated that this recognition by TGA of site's manufacturing and compliance capabilities would pave the path for direct supplies of API to this stringent regulated territory as well as supplies to drug product manufacturers across the globe, who are supplying their finished product in the territory of Australia and New Zealand. Post this recognition, the company expects to attract more CDMO contracts from existing and new clients. Bajaj Healthcare a leading manufacturer of APIs, intermediates and formulations. It has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America. The company reported standalone net profit of Rs 94.64 crore in Q2 FY25 as compared with net loss of Rs 34.60 crore in Q2 FY24. Revenue from operations jumped 31.5% YoY to Rs 133.08 crore in Q2 FY25. The counter hit a 52-week high of Rs 452.05 in today's intraday session.Powered by Capital Market - Live

1 day agoCapital Market - Live
Spotlight
Bajaj Healthcare reports turnaround Q2 performance

Revenue from operations jumped 31.5% YoY to Rs 133.08 crore in Q2 FY25. Profit before tax (PBT) surged 137.4% to Rs 12.44 crore in Q2 FY25 as compared with Rs 5.24 crore posted in same quarter last year. EBITDA stood at Rs 24.52 crore during the quarter, registering the growth 29.4% as compared with Rs 189.5 crore in Q2 FY24. EBITDA fell to 18.4% in Q2 FY25 as compared with 18.7% in Q2 FY24. In Q2 FY25, revenue from opium processing skyrocketed 582.9% YoY to Rs 13.66 crore, while API (domestic) and formulations jumped 21.8% and 27.7% YoY, respectively. API (exports) grew 12.3% YoY to Rs 29.20 crore. Anil Jain, managing director, Bajaj Healthcare, said, 'I am delighted to present the impressive results of our second quarter for FY25. Our revenue from operations surged by approximately 32% year-on-year led by robust performance across all segments ' this coupled with expansion in our margins resulted in a 90% year-on-year increase in our bottom line from our continuing operations We continue to undertake all efforts to sell the assets from the discontinued operations and to use the proceeds for further debt repayment and minimize the losses from the discontinued operations. We have materially repaid our borrowings to the tune of Rs 150.0 crore and this has further strengthened our financial position. Contribution from our API and Formulation segments rose, with both registering strong growth at 19% and 28%, respectively. The domestic demand has remained quite encouraging and has been a source of strength even as export markets are still largely wrestling sticky inflation and elevated freights. Another key highlight was the exceptional performance of our Opium Processing business, which grew multi-fold year-on-year. The segment has quickly become a meaningful growth driver for our overall business. We are focused on expanding capacity to meet increasing government requirements and sustain its high growth trajectory going forward. Bajaj Healthcare a leading manufacturer of APIs, intermediates and formulations. It has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America. The counter rallied 7.75% to settle at Rs 390.75 on Thursday, 14 November 2024.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Earnings
Bajaj Healthcare reports standalone net profit of Rs 9.46 crore in the September 2024 quarter

Net profit of Bajaj Healthcare reported to Rs 9.46 crore in the quarter ended September 2024 as against net loss of Rs 3.46 crore during the previous quarter ended September 2023. Sales rose 31.50% to Rs 133.09 crore in the quarter ended September 2024 as against Rs 101.21 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales133.09101.21 31 OPM %18.4218.71 - PBDT19.2511.90 62 PBT12.445.24 137 NP9.46-3.46 LP Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Bajaj Healthcare announces board meeting date

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Bajaj Healthcare enters into API development and supply agreement with European company

Bajaj Healthcare has entered into a development and supply agreement for an Active Pharmaceutical Ingredient (API) with a European entity. This API after its development will be initially supplied in small quantities and will be used by the EU partner to carry out clinical trials for an alternative indication. Based on the outcome of these trials, the supplies will be done from the Company's FDA approved manufacturing facility situated at Savli, Vadodara.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Bajaj Healthcare gains on inking pact with European entity

After the development, the API will be initially supplied in small quantities and will be used by the EU partner to carry out clinical trials for an alternative indication. The trust reposed in the company by the EU partner for sourcing clinical trial quantities is a testimony of the company's development and manufacturing capabilities along with the good manufacturing practices (GMP) compliance at company's manufacturing units. Based on the outcome of these trials, the supplies will be done from the company's FDA approved manufacturing facility situated at Savli, Vadodara. Bajaj Healthcare a leading manufacturer of APIs, intermediates and formulations. It has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America. The company's standalone net profit jumped 14.1% to Rs 8.02 crore in Q1 FY25 as against 7.03 crore recorded in Q1 FY24. Revenue from operations increased 1.9% YoY to Rs 132.25 crore in Q1 FY25.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Board of Bajaj Healthcare approves preferential allotment of shares and warrants

The Board of Bajaj Healthcare at its meeting held on 19 September 2024 has approved the allotment of 39,84,852 equity shares of the Company of face value of Rs. 5/- each fully paid at a price of Rs. 338/-, (including a premium of Rs. 333/- per equity share) aggregating to Rs. 1,34,68,79,976/-. The board has also approved allotment of 20,79,409 fully convertible warrants with each warrant convertible into or exchangeable for One (1) fully paid-up equity share of the Company of face value of Rs. 5/- each at an issue price of Rs. 338/-(including a premium of Rs. 333/-) per warrant, aggregating to Rs. 70,28,40,242/- to the Promoter, Promoter Group and Persons belonging to Non-Promoter category on Preferential Basis. Consequent to the aforesaid allotment of Equity Shares, the paid-up equity share capital of the Company stands increased to Rs. 15,79,16,260 comprising of 3,15,83,252 equity shares of the face value of Rs. 5/- each.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Bajaj Healthcare schedules AGM

Bajaj Healthcare announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Bajaj Healthcare announces board meeting date

Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 19 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Bajaj Healthcare reports standalone net profit of Rs 7.13 crore in the June 2024 quarter

Net profit of Bajaj Healthcare reported to Rs 7.13 crore in the quarter ended June 2024 as against net loss of Rs 48.21 crore during the previous quarter ended June 2023. Sales rose 1.93% to Rs 132.25 crore in the quarter ended June 2024 as against Rs 129.74 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales132.25129.74 2 OPM %18.5316.76 - PBDT16.9113.22 28 PBT10.186.91 47 NP7.13-48.21 LP Powered by Capital Market - Live

3 months agoCapital Market - Live